COMBINED TISSUE PLASMINOGEN ACTIVATOR AND AN NK1 TACHYKININ RECEPTOR ANTAGONIST: AN EFFECTIVE TREATMENT FOR REPERFUSION INJURY FOLLOWING ACUTE ISCHEMIC STROKE IN RATSTURNER, R. J; VINK, R.Neuroscience. 2012, Vol 220, pp 1-10, issn 0306-4522, 10 p.Article

The tachykinin NK₁ receptor. Part II: distribution and pathophysiological rolesQUARTARA, L; MAGGI, C. A.Neuropeptides (Edinburgh). 1998, Vol 32, Num 1, pp 1-49, issn 0143-4179Article

The role of the amino-terminal domain of tachykinins in neurokinin-1 receptor signaling and desensitizationVIGNA, Steven R.Neuropeptides (Edinburgh). 2003, Vol 37, Num 1, pp 30-35, issn 0143-4179, 6 p.Article

Aprepitant: drug-drug interactions in perspectiveAAPRO, M. S; WALKO, C. M.Annals of oncology. 2010, Vol 21, Num 12, pp 2316-2323, issn 0923-7534, 8 p.Article

Disposition and Metabolism of Radiolabeled Casopitant in HumansPELLEGATTI, Mario; BORDINI, Ellenia; FIZZOTTI, Patrizia et al.Drug metabolism and disposition. 2009, Vol 37, Num 8, pp 1635-1645, issn 0090-9556, 11 p.Article

Analysis of an intact G-protein coupled receptor by MALDI-TOF mass spectrometry : Molecular heterogeneity of the tachykinin NK-1 receptorRIVES, Isabel D; SACHON, Emmanuelle; BOLBACH, Gerard et al.Analytical chemistry (Washington, DC). 2007, Vol 79, Num 6, pp 2189-2198, issn 0003-2700, 10 p.Article

New antiemetic drugsROILA, F; FATIGONI, S.Annals of oncology. 2006, Vol 17, issn 0923-7534, ii96-ii100, SUP2Conference Paper

Involvement of tachykinin NK₁ receptor in the behavioral and immunological responses to swimming stress in miceTEIXEIRA, Raquel M; DE LIMA, Thereza C. M.Neuropeptides (Edinburgh). 2003, Vol 37, Num 5, pp 307-315, issn 0143-4179, 9 p.Article

Rolapitant for the Prevention of Postoperative Nausea and Vomiting: A Prospective, Double-Blinded, Placebo-Controlled Randomized TrialGAN, Tong J; JIEZHUN GU; CREED, Mary R et al.Anesthesia and analgesia. 2011, Vol 112, Num 4, pp 804-812, issn 0003-2999, 9 p.Article

Substance P (NK₁) receptor antagonists-analgesics or not?BOYCE, S; HILL, R. G.Handbook of experimental pharmacology. 2004, Vol 164, pp 441-457, issn 0171-2004, 17 p.Article

Inflammation-induced up-regulation of neurokinin 1 receptors in rat glabrous skinCARLTON, Susan M; COGGESHALL, Richard E.Neuroscience letters. 2002, Vol 326, Num 1, pp 29-32, issn 0304-3940Article

Tachykinin NK₁ receptor antagonistsPATACCHINI, R; MAGGI, C. A.Handbook of experimental pharmacology. 2004, Vol 164, pp 173-218, issn 0171-2004, 46 p.Article

Generation of a transgenic model to address regulation and function of the human neurokinin 1 receptor (NK1R)VASILIOU, A. S; MACKENZIE, A; MORRIS, R et al.Neuropeptides (Edinburgh). 2007, Vol 41, Num 4, pp 195-205, issn 0143-4179, 11 p.Article

Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy SubjectsMARBURY, Thomas C; BO JIN; PANEBIANCO, Deborah et al.Anesthesia and analgesia. 2009, Vol 109, Num 2, pp 418-425, issn 0003-2999, 8 p.Article

Antitussive activity of the tachykinin NK1 receptor antagonist, CP-99994, in dogsCHAPMAN, Richard W; HOUSE, Aileen; FEI LIU et al.European journal of pharmacology. 2004, Vol 485, Num 1-3, pp 329-332, issn 0014-2999, 4 p.Article

Localization of the neurokinin 1 (NK-1) receptor in the human antrum and duodenumSMITH, V. C; SAGOT, M. A; COURAUD, J.-Y et al.Neuroscience letters. 1998, Vol 253, Num 1, pp 49-52, issn 0304-3940Article

Stress-induced increase of cortical dopamine metabolism: attenuation by a tachykinin NK₁ receptor antagonistHUTSON, Peter H; PATEL, Shil; JAY, Mark T et al.European journal of pharmacology. 2004, Vol 484, Num 1, pp 57-64, issn 0014-2999, 8 p.Article

Pharmacology of MEN 11467 : a potent new selective and orally-effective peptidomimetic tachykinin NK₁ receptor antagonistCIRILLO, R; ASTOLFI, M; MAGGI, C. A et al.Neuropeptides (Edinburgh). 2001, Vol 35, Num 3-4, pp 137-147, issn 0143-4179Article

Differences in the expression of neurokinin receptor in neural and bone marrow mesenchymal cells: implications for neuronal expansion from bone marrow cellsBANDARI, P. S; QIAN, J; YEHIA, G et al.Neuropeptides (Edinburgh). 2002, Vol 36, Num 1, pp 13-21, issn 0143-4179Article

A substance P antagonist improves outcome when administered 4 h after onset of ischaemic strokeTURNER, Renee J; HELPS, Stephen C; THORNTON, Emma et al.Brain research. 2011, Vol 1393, pp 84-90, issn 0006-8993, 7 p.Article

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PETRIDLER, Khanum; GUNN, Roger N; POGGESI, Italo et al.Journal of psychopharmacology (Oxford). 2014, Vol 28, Num 3, pp 244-253, issn 0269-8811, 10 p.Article

Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndromeCRISTOFORI, F; THAPAR, N; SALIAKELLIS, E et al.Alimentary pharmacology & therapeutics. 2014, Vol 40, Num 3, pp 309-317, issn 0269-2813, 9 p.Article

Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to C0₂ challengePOMA, Stefano Zanone; MERLO-PICH, Emilio; BETTICA, Paolo et al.Journal of psychopharmacology (Oxford). 2014, Vol 28, Num 5, pp 491-497, issn 0269-8811, 7 p.Article

Application of LC-NMR and HR-NMR to the characterization of biphenyl impurities in the synthetic route development for vestipitant, a novel NK1 antagonistPROVERA, Stefano; MARTINI, Luca; GUERCIO, Giuseppe et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 53, Num 3, pp 389-395, issn 0731-7085, 7 p.Article

Immunolocalization of NK-1 Receptor and Substance P in Human Normal PlacentaMUNOZ, M; PAVON, A; ROSSO, M et al.Placenta (Eastbourne). 2010, Vol 31, Num 7, pp 649-651, issn 0143-4004, 3 p.Article